Head-to-head evidence
Apomorphine (Apokyn) vs rotigotine
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Parkinson's Disease
Shared mechanism: dopamine · full Parkinson's Disease pipeline
Apomorphine (Apokyn)
Marketed by Supernus Pharmaceuticals
NCT00142545 · Phase 3 · completed
The study was non-randomized, open-label, and had no comparator arm; all 800 participants received apomorphine. Its primary outcomes focused on safety monitoring, and no primary endpoint results were posted, so there is no controlled comparison showing benefit.
Next expected readout: December 2027 · NCT04957095 (registry estimate)
rotigotine · Neupro
Marketed by UCB
NCT00244387 · Phase 3 · completed
Although the registry reports a randomized, double-blind design with 506 participants, it lists no comparator arm, so the treatment cannot be evaluated against another treatment or placebo from the available record. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Apomorphine (Apokyn)'s landscape · rotigotine's landscape